PF-06480605 is a Monoclonal Antibody owned by Pfizer, and is involved in 6 clinical trials, of which 4 were completed, 1 is ongoing, and 1 is planned.
PF-06480605 exhibits therapeutic intervention by blocking tumor necrosis factor (TNF)-like cytokine 1A (TL1A)/TNF superfamily member 15 (TNFSF15). TNFSF15 is a proinflammatory cytokine and TNF alpha superfamily member that is linked to inflammatory bowel disease (IBD). TL1A induces proinflammatory cytokines, including TNF alpha, from isolated human CD4+CD161+ T cells, whereas these cells were resistant to TNF alpha treatment. Thus anti-TNF alpha failed to block TL1A-induced cytokine production which significantly and selectively decreases the CD161 and TL1A expression thus helps in getting rid of the disease.
The revenue for PF-06480605 is expected to reach a total of $308m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the PF-06480605 NPV Report.
PF-06480605 is originated and owned by Pfizer.
PF-06480605 is under development for the treatment of moderate to severe ulcerative colitis. The drug candidate is a fully human immunoglobulin G1 monoclonal antibody, which is administered intravenously and subcutaneously. The drug candidate acts by targeting TNFSF15. It is a new molecular entity. It was also under development for Crohn's disease.
Pfizer discovers, develops, manufactures and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, cancer, inflammation, immune disorders and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US.
The company reported revenues of (US Dollars) US$81,288 million for the fiscal year ended December 2021 (FY2021), an increase of 95.2% over FY2020. In FY2021, the company’s operating margin was 29.1%, compared to an operating margin of 18.8% in FY2020. In FY2021, the company recorded a net margin of 27%, compared to a net margin of 22% in FY2020.
Quick View – PF-06480605
|Highest Development Stage|